Autres langues Daiichi Sankyo Co., Ltd.

Actions

4568

JP3475350009

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
5 829 ^JPY	+0,97 %		+4,50 %	+50,54 %

04/06	Daiichi Sankyo rachète des actions pour plus de 29 milliards de yens en mai	MT
03/06	AstraZeneca annonce que le traitement potentiel du cancer du sein réduit le risque de progression de la maladie de 38%.	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May	04/06
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%	03/06
Daiichi Sankyo : ASCO highlight briefing session materia	03/06
Daiichi Sankyo : ASCO presentation materia	03/06
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug	03/06
Astra's Enhertu breast cancer trial shows 'unprecedented' results	02/06
Astra's Enhertu delays breast cancer in patients with low HER2 levels	02/06
Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified	02/06
Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial	02/06
AstraZeneca and Daiichi Sankyo Announce Positive Results from the DESTINY-Breast06 Phase III Trial Showed That ENHERTU Metastatic Breast Cancer and the Overall Trial Population	02/06
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy	02/06
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	28/05
RevolKa Signed Master Service Agreement with Daiichi Sankyo	28/05
RevolKa Signs Master Service Agreement with Daiichi Sankyo	28/05
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients	27/05
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial	27/05
AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival	27/05
Astra, Daiichi hail positive survival data for Dato-DXd	27/05
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial	27/05
Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial	27/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Daiichi Sankyo Co., Ltd.

Actions

4568

JP3475350009

Autres langues

Filtres